ARTICLES

Filter  
Active filters 0
Remove
  

Refine your searches by:

Collections
Medicine / Sub specialtie
Public health
Medicine / Pharmacology
Sports
Medicine / Cardiology
Medicine / Dentistry

Languages
English

Countries
USA
Pakistan
China
Portugal
Poland
Ukraine

Years
2021
2020
2019
2018
2017
2016
2015
2014
2013

Filter  
 
27  Articles
1 of 4 pages  |  10  records  |  more records»
Aims: Liraglutide has been shown to reduce cardiovascular mortality in a cardiovascular safety study, but it is not known to what extent these results will be replicated in real practice with people with diabetes treated with liraglutide in the UK. We wis... see more

LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) was an FDA-mandated cardiovascular outcome trial with liraglutide and was the first trial with a glucagon-like peptide-1 (GLP-1) receptor agonist to demonstra... see more

Background and Objective: GLP-one receptor agonists are amongst the unique antidiabetes medications that have significant metabolic and cardiovascular benefits in addition to glucose lowering effect. To best of our knowledge, there is no published data on... see more

People with type 2 diabetes mellitus experience an increased prevalence of non-alcoholic fatty liver disease (NAFLD) compared with the general population and often with worse outcomes. As part of the ABCD Liraglutide Nationwide Audit Programme, we obtaine... see more

Background: Liraglutide may be less effective in patients with more advanced type 2 diabetes. This study from the Association of British Clinical Diabetologists Nationwide Liraglutide Audit analysed changes in HbA1c of patients after 26 weeks of trea... see more

Objectives: To investigate the effects of a glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide on podocytes, inflammation, and oxidative stress in patients with diabetic nephropathy (DN).Methods: Eighty-four DN patients treated by the departme... see more

Saxenda, Liraglutide 3.0 mg, is a glucagon-like peptide-1 (GLP-1) analogue that is licensed for the treatment of adults with overweight and obesity. In this commentary we review the NICE technology appraisal (TA664) on the use of Saxenda in the National H... see more

Background: American Diabetes Association (ADA) made conspicuous changes in its 2019 Standards ofCare Diabetes guidelines by choosing Glucagon like Peptide 1 (GLP1) receptor agonists and SodiumGlucose co-transporter 2 (SGLT2) inhibitors as the second line... see more


1 of 4 pages  |  10  records  |  more records»